A Prospective Clinical Investigation of DMFI300 for Treating Nasolabial Folds

NCT07467239

Status	RECRUITING
Phase	Not Applicable
Sponsor	Samyang Biopharmaceuticals Corporation
Enrollment	30 participants

Key Eligibility Criteria

Inclusion (5)

- Men and women aged 18-70 years.
- Score of 3 to 4 on the Wrinkle Severity Rating Scale (WSRS) for both nasolabial folds.
- Willing and able to provide written informed consent.
- Willing to comply with study procedures and follow-up visits.
- Willing to refrain from other facial cosmetic procedures affecting the nasolabial folds during the study.

Exclusion (5)

- Use of antiplatelet agents, vitamin E, or NSAIDs within 2 weeks before screening or planned use within 2 weeks after treatment.
- History or presence of bleeding disorders.
- Participation in another clinical investigation within 1 month prior to screening.
- Pregnant or breastfeeding women, or women planning pregnancy during the study.
- Women of childbearing potential not using an effective method of contraception.

Locations (1 total)

Ocean Clinic, Marbella, Spain